We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $445.81 · 27 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Adding Scientific Depth Amid RNAi Pipeline Scrutiny - simplywall.st
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Adding Scientific Depth Amid RNAi Pipeline Scrutiny simplywall.st
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) ChartMill
Alnylam (NASDAQ: ALNY) expands board and details 2026 shareholder meeting votes - Stock Titan
Alnylam (NASDAQ: ALNY) expands board and details 2026 shareholder meeting votes Stock Titan
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $445 - 富途牛牛
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $445 富途牛牛
Citi Initiates Alnylam (ALNY) With Buy Rating - Yahoo Finance
Citi Initiates Alnylam (ALNY) With Buy Rating Yahoo Finance
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $2.17 | — | — | $1.32B | — | Scheduled |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-1.53 | — | — | $1.66B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.66 | — | — | $1.15B | Reported |
| FY2025 Q1 | 2024. 03. 31. | Time TBD | — | $-0.52 | — | — | $494.33M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 19. | Citigroup | — | Initiate coverage | — → Buy | — | Citigroup: Buy |
| 2026. 05. 05. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 02. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 05. 01. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2026. 04. 14. | Truist Securities | — | Maintain | Buy → Buy | — | Truist Securities: Buy |
| 2026. 03. 26. | Chardan Capital | — | Maintain | Buy → Buy | — | Chardan Capital: Buy |
As of FY2025Q3 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,992,577 | $659.28B | 0.56% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 616,120 | $245B | 0.38% | — | New position |